Call +41-61-926-60-40 Fax +41-61-926-60-49

Selonsertib (free base)

SYN-1231-M001 1 mg INQ
SYN-1231-M005 5 mg INQ
SYN-1231-M010 10 mg INQ
SYN-1231-M050 50 mg INQ
SYN-1231-M100 100 mg INQ
Actions
Select size:

* Required Fields

Amount:
Add to Cart
Call +41-61-926-60-40
Fax +41-61-926-60-49
Contact Us!
MSDS

Additional Information

Product Data
Synonyms GS-4997 (free base); 5-(4-Cyclopropyl-1H-imidazol-1-yl)-2-fluoro-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-4-methylbenzamide
Properties
Formula C24H24FN7O
MW 445.5
CAS 1448428-04-3
Purity ≥95%
Appearance Solid.
Solubility Soluble in DMSO. Insoluble in water.
Origin Manufactured by SynKinase.
Other Product Data Target: ASK1 | Kinase Group: Ser⁄Thr Kinases |

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.
InChi Key YIDDLAAKOYYGJG-UHFFFAOYSA-N
Product Type Chemical
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Keep cool and dry.
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Related Products

Product Description

Selonsertib, also known as GS-4997, is an orally bioavailable inhibitor of apoptosis signal-regulating kinase 1 (ASK1), with potential anti-inflammatory, antineoplastic and anti-fibrotic activities. GS-4997 targets and binds to the catalytic kinase domain of ASK1 in an ATP-competitive manner. GS-4997 prevents the production of inflammatory cytokines, down-regulates the expression of genes involved in fibrosis, suppresses excessive apoptosis and inhibits cellular proliferation.

Product References

  1. Design of a phase 2 clinical trial of an ASK1 inhibitor, GS-4997, in patients with diabetic kidney disease: J.H. Lin, et al.; Nephron 129, 29 (2015)
  2. A Quantitative Framework to Evaluate Proarrhythmic Risk in a First-in-Human Study to Support Waiver of a Thorough QT Study: C.H. Nelson, et al.; Clin. Pharmacol. Ther. 98, 630 (2015)
No reviews for this product yet.